2026-04-17T02:58:29Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/84512025-10-24T10:44:34Zcom_2072_378070com_2072_378040col_2072_378092

Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis Innominato, Pasquale Fabio Cailliez, Valérie Allard, Marc Antoine Lopez-Ben, Santiago Ferrero, Alessandro Pinto Marques, Hugo Dopazo Taboada, Cristina Fetge - Càncer - Cirurgia Còlon - Càncer - Cirurgia Avaluació de resultats (Assistència sanitària) ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Digestive System Surgical Procedures::Hepatectomy DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms Other subheadings::Other subheadings::Other subheadings::/surgery DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::procedimientos quirúrgicos del sistema digestivo::hepatectomía ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas Otros calificadores::Otros calificadores::Otros calificadores::/cirugía ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales Liver metastases; Liver resection; Preoperative chemotherapy Metástasis hepáticas; Resección hepática; Quimioterapia preoperatoria Metàstasis hepàtiques; Resecció hepàtica; Quimioteràpia preoperatòria Background: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initially-irresectable CLM. The main outcome was Overall Survival (OS) after surgery. Disease-free (DFS) and hepatic-specific relapse-free survival (HS-RFS) were secondary outcomes. PO-SACT features included duration (cumulative number of cycles), choice of the cytotoxic backbone (oxaliplatin- or irinotecan-based), fluoropyrimidine (infusional or oral) and addition or not of targeted monoclonal antibodies (anti-EGFR or anti-VEGF). Results: A total of 2793 patients in the database had received PO-SACT for initially irresectable diseases. Short (<7 or <13 cycles in 1st or 2nd line) PO-SACT duration was independently associated with longer OS (HR: 0.85 p = 0.046), DFS (HR: 0.81; p = 0.016) and HS-RFS (HR: 0.80; p = 0.05). All other PO-SACT features yielded basically comparable results. Conclusions: In this international cohort, provided that PO-SACT allowed conversion to resectability in initially irresectable CLM, surgery performed as soon as technically feasible resulted in the best outcomes. When resection was achieved, our findings indicate that the choice of PO-SACT regimen had a marginal if any, impact on outcomes. 2025-10-24T10:44:34Z 2025-10-24T10:44:34Z 2025-10-24T10:44:34Z 2022-11-11T12:45:09Z 2022-11-11T12:45:09Z 2022-09-05 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/8451 Cancers;14(17) https://doi.org/10.3390/cancers14174340 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess MDPI Scientia